Sorrento Announces Full Repayment of Outstanding Term Loans
The prepaid debt, comprised of an initial
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T”), antibody-drug conjugates (“ADC”), and clinical stage oncolytic virus (“Seprehvir®”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™ and COVI-KILLER™.
Sorrento's commitment to Saving-Life™ and Improving-Life™ medicine and therapy for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. Resiniferatoxin is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on
For more information visit www.sorrentotherapeutics.com
Media and Investor Relations
Sorrento® and the Sorrento logo are registered trademarks of
G-MAB™, COVI-GUARD™, COVI-SHIELD™, COVIDTRAP™, ACE-MAB™, COVI-KILLER™ and COVI-CELL™, Saving-Life™ and Improving-Life™ are trademarks of
ZTlido® is a trademark owned by
Seprehvir® is a registered trademark of Virttu Biologics Limited, a wholly-owned subsidiary of
All other trademarks are the property of their respective owners.
Source: Sorrento Therapeutics, Inc.